May 18, 2016 7:25 pm EDT UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2016 5:00 pm EDT Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 09, 2016 8:00 am EDT Atara Bio’s Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress
May 05, 2016 8:00 am EDT Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
Apr 19, 2016 5:15 pm EDT Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
Mar 28, 2016 4:05 pm EDT Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences
Mar 23, 2016 9:15 am EDT Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder
Mar 16, 2016 4:45 pm EDT Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting
Mar 03, 2016 4:05 pm EST Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights